The Current Management of Pancreatic Neuroendocrine Tumors

Advances in Surgery

Volumn 46, Issue 1, 2012, Pages 283-296

  Ellison, Trevor A ^a   Edil, Barish H ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Hormones; Islet cell tumor; Neuroendocrine neoplasm; Neuroendocrine tumor; Pancreas; PanNET

Indexed keywords

DIAGNOSTIC IMAGING; GASTRINOMA; HUMAN; INSULINOMA; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; REVIEW; SOMATOSTATINOMA; TREATMENT OUTCOME; VIPOMA;

DIAGNOSTIC IMAGING; GASTRINOMA; HUMANS; INSULINOMA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; SOMATOSTATINOMA; TREATMENT OUTCOME; VIPOMA;

EID: 84863470548     PISSN: 00653411     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yasu.2012.04.002     Document Type: Review

References (19)

1. NCI at NIH. Pancreatic neuroendocrine tumors (islet cell tumors) treatment (PDQ ®). Available at: Accessed April 2, 2012. http://www.cancer.gov/cancertopics/pdq/treatment/isletcell/HealthProfessional.
2. Kulke M.H., Siu L.L., Tepper J.E., et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the national cancer institute neuroendocrine tumor clinical trials planning meeting. J Clin Oncol 2011, 29(7):934-943.
3. O'Grady H.L., Conlon K.C. Pancreatic neuroendocrine tumours. Eur J Surg Oncol 2008, 34:324-332.
4. Johns Hopkins Medicine, The Sol Goldman Pancreatic Cancer Research Center. Islet cell tumors of the pancreas/endocrine neoplasms of the pancreas. Available at: Accessed April 2, 2012. http://pathology.jhu.edu/pc/TreatmentEndocrine.php?area=tr#causes.
5. Rindi G. The ENETS guidelines: the new TNM classification system. Tumori 2010, 96(5):806-809.
6. Oberstein P.E., Saif M.W. Novel agents in the treatment of unresectable neuroendocrine tumors. JOP 2011, 12(4):358-361.
7. Morrow E.H., Norton J.A. Management of pancreatic islet cell tumors excluding gastrinoma. Current surgical therapy 2011, 456-460. Elsevier Saunders, Philadelphia. 10th edition. J.L. Cameron, A.M. Cameron (Eds.).
8. Taouli B., Ghouadni M., Corréas J.M., et al. Spectrum of abdominal imaging findings in von Hippel-Lindau disease. Am J Roentgenol 2003, 181(4):1049-1054.
9. Goldman J.A., Blanton W.P., Hay D.W., et al. False-positive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2009, 7(5):600-602.
10. Gouya H., Vignaux O., Augui J., et al. CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. Am J Roentgenol 2003, 181(4):987-992.
11. Saif M.W. Pancreatic neoplasm in 2011: an update. JOP 2011, 12(4):316-321.
12. Jensen R.T., Fave G.D. Promising advances in the treatment of malignant pancreatic endocrine tumors. N Engl J Med 2011, 364(6):564-565.
13. Raymond E., Dahan L., Raoul J.-L., et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011, 364(6):501-513.
14. Yao J.C., Shah M.H., Ito T., et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011, 364(6):514-523.
15. Jiao Y., Shi C., Edil B.H., et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011, 331(6021):1199-1203.
16. Seregni E., Ferrari L., Bajetta E., et al. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 2001, 12(Suppl 2):S69-S72.
17. Tomassetti P., Migliori M., Simoni P., et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumors. Eur J Gastroenterol Hepatol 2001, 13(1):55-58.
18. Dimou A.T., Syrigos K.N., Saif M.W. Neuroendocrine tumors of the pancreas: what's new. JOP 2010, 11(2):135-138.
19. Celinski S.A., Nguyen K.T., Steel J.L., et al. Multimodality management of neuroendocrine tumors metastatic to the liver. 2010 Gastrointestinal Cancers Symposium 2010, Pittsburgh (PA), UPMC Neuroendocrine Cancer Treatment Center.